TABLE 1.
MRSA bioburdens in blood, vegetations, kidney, and spleen in rabbit IE model
| Treatment group (n = 10 animals/group)a | Mean log10 CFU/g tissue ± SD (no. of sterile cultures/total no. of cultures)b |
Mean log10 CFU/ml blood ± SD (pretherapy baseline) | ||
|---|---|---|---|---|
| Vegetations | Kidney | Spleen | ||
| Untreated control | 8.02 ± 0.44 (0/10) | 6.77 ± 0.35 (0/10) | 6.02 ± 0.20 (0/10) | 3.18 ± 0.45 |
| Dap 4 mg/kg i.v. QD for 4 days | 5.44 ± 0.53* (0/10) | 4.66 ± 0.41* (0/10) | 4.64 ± 0.46* (0/10) | 3.33 ± 0.40 |
| LSVT-1701 32.5 mg/kg i.v. single dose + Dap 4 mg/kg i.v. QD for 4 days | 5.17 ± 1.09*% (0/10) | 4.34 ± 0.45*% (0/10) | 4.27 ± 0.33*% (0/10) | 3.22 ± 0.49 |
| LSVT-1701 32.5 mg/kg i.v. QD for 2 days + Dap 4 mg/kg i.v. QD for 4 days | 3.06 ± 0.81*@#% (0/10) | 2.95 ± 0.70*@#% (0/10) | 2.64 ± 0.67*@#% (0/10) | 3.37 ± 0.27 |
| LSVT-1701 32.5 mg/kg i.v. QD for 4 days + Dap 4 mg/kg i.v. QD for 4 days | 1.01 ± 0.16*@# (10/10) | 0.91 ± 0.09*@# (10/10) | 0.82 ± 0.23*@# (10/10) | 3.30 ± 0.22 |
| LSVT-1701 50 mg/kg i.v. single dose + Dap 4 mg/kg i.v. QD for 4 days | 1.64 ± 0.73*@ (4/10) | 1.56 ± 0.61*@$ (3/10) | 1.06 ± 0.53*@ (7/10) | 3.50 ± 0.39 |
| LSVT-1701 50 mg/kg i.v. QD for 4 days + Dap 4 mg/kg i.v. QD for 4 days | 0.93 ± 0.10*@% (10/10) | 0.89 ± 0.10*@$% (10/10) | 0.85 ± 0.11*@% (10/10) | 3.42 ± 0.33 |
a
Dap, daptomycin.
b
*, P < 0.05 for LSVT-1701 treatment groups compared to untreated control; @, P < 0.05 for LSVT-1701 treatment groups compared to daptomycin alone; #, P < 0.05 for LSVT-1701 32.5 mg/kg i.v. QD for 4 days compared to i.v. QD for 2 days and single dose; $, P < 0.05 for LSVT-1701 50 mg/kg i.v. QD for 4 days compared to single dose; %, P < 0.05 for LSVT-1701 50 mg/kg i.v. QD for 4 days compared to 32.5 mg/kg i.v. QD for 2 days and single dose.